Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go hand in hand. But if you’re considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage, meaning they have no commercialized drugs or therapeutics. That also means negative earnings (they aren’t profitable) and little to no revenue. Success often depends on the outcome of a single clinical-stage program, and even if a product advances through trials, profitability can still be years away. Only after reaching those milestones do companies typically attract analyst coverage and institutional investment. A tiny government task force just wrapped up 20 years of work.
And buried in their federal filings, I found something remarkable:
American citizens now have a legal birthright claim to something previously inaccessible.
Under U.S. law, you can stake your claim right now. The name and ticker are available here now >>> Still, landing on a successful small-cap biotech can produce lottery-like returns: 3x, 5x, or even 10x gains are possible in an instant. Many investors interested in penny stocks therefore spread a lump sum across multiple biotech names. If this is a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risk but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed already has a commercially available product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a leading digital health pioneer in Germany. With more than 60,000 new colorectal cancer cases annually in Germany, the opportunity is meaningful. The company is also developing a non-invasive, blood-based screening test for early detection of pancreatic cancer and reported positive topline results in October. However, commercial approval for that test is still years away. Risks remain substantial. ColoAlert is not yet available in the United States, and despite early European sales and expansion plans for South America, revenue is still minimal. That uncertainty is reflected in the company’s Sept. 26 SEC filing, which included “Going Concern” language. Since then Mainz Biomed has filed a $150 million mixed shelf offering. That financing helps keep the MYNZ share price above $1 and avoids a delisting notice for now. The company is in a race to generate meaningful revenue. If it succeeds in scaling ColoAlert or advancing its pancreatic program toward commercialization, even a small investment today could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech that offers a potentially disruptive approach to antiviral treatment—but it also carries the financial risks typical of speculative biotech investing. The company is developing a novel class of antivirals using its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces, luring viruses to bind with them and neutralizing the pathogens before they can infect real cells. If validated in human trials, this would represent a fundamentally new method for treating infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has produced encouraging preclinical data indicating strong antiviral activity. But like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to advance its programs. Recent filings show limited cash on hand, and investors should expect the possibility of future dilution. Still, if even one candidate advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
